Testosterone deficiency and the metabolic syndrome

References

• Bjorntorp P. Abdominal obesity and the metabolic syndrome. Ann Med 1992; 24: 465–468
   PubMed Web of Science ®Google Scholar
• Despres J P, Marette A. Relation of components of insulin resistance syndrome to coronary disease risk. Curr Opin Lipidol 1994; 5: 274–289
   PubMedGoogle Scholar
• Assmann G, Nofer J R, Schulte H. Cardiovascular risk assessment in metabolic syndrome: view from PROCAM. Endocrinol Metab Clin North Am 2004; 33: 377
   PubMed Web of Science ®Google Scholar
• Ritchie S A, Ewart M A, Perry C G, Connell J M, Salt I P. The role of insulin and the adipocytokines in regulation of vascular endothelial function. Clin Sci (London) 2004; 107(6)519–532
   PubMed Web of Science ®Google Scholar
• Bays H, Mandarino E, Defronzo R. A role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol & Metab 2004; 89: 463–478
   PubMed Web of Science ®Google Scholar
• Rigalleau V, Binnert C, Minehira K, Stefanoni N, Schneiter, et al. In normal men, free fatty acids reduce peripheral but not splanchnic glucose uptake. Diabetes 2001; 50: 727–732
   PubMed Web of Science ®Google Scholar
• Winzell M S, Svensson H, Enerback S, Ravnskjaer K, Mandrup S, et al. Pancreatic beta-cell lipotoxicity induced by overexpression of hormone-sensitive lipase. Diabetes 2003; 52(8)2057–2066
   PubMed Web of Science ®Google Scholar
• McGarry J D, Dobbins R L. Fatty acids, lipotoxicity and insulin secretion. Diabetologia 1999; 42: 128–138
   PubMed Web of Science ®Google Scholar
• Festa A, D'Agostino R J, Howard G, Mykkanen L, Tracy R P, Haffner S M. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42–47
   PubMed Web of Science ®Google Scholar
• Quinones M J, Nicholas S B, Lyon C J. Insulin resistance and the endothelium. Curr Diab Rep 2005; 5: 246–253
   PubMedGoogle Scholar
• Meade T W, Ruddock V, Stirling Y, et al. Fibrinolytic activity, clotting factors, and long-term incidence of ischemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076–1079
   PubMed Web of Science ®Google Scholar
• Kohler H P, Grant P J. Mechanisms of disease: plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342: 1792–1801
   PubMed Web of Science ®Google Scholar
• Hamsten A, Wiman B, de Faire U, et al. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557–1563
   PubMed Web of Science ®Google Scholar
• Ridker P M, Vaughan D E, Stampfer M J, et al. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165–1168
   PubMed Web of Science ®Google Scholar
• Tsai A W, Cushman M, Rosamond W D, et al. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002; 162: 1182–1189
   PubMed Web of Science ®Google Scholar
• Sobel B E, Woodcock-Mitchell J, Schneider D J, et al. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation 1998; 97: 2213–2221
   PubMed Web of Science ®Google Scholar
• Thompson S G, Kienast J, Pyke S DM, et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635–641
   PubMed Web of Science ®Google Scholar
• Hamsten A, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3–9
   PubMed Web of Science ®Google Scholar
• Ruano M, Silvestre V, Castro R, et al. Morbid obesity, hypertensive disease and the renin-angiotensin-aldosterone axis. Obes Surg 2005; 15: 670–676
   PubMed Web of Science ®Google Scholar
• Gerald B. Phillips Relationship between Serum Sex Hormones and Glucose, Insulin, and Lipid Abnormalities in Men with Myocardial Infarction PNAS. 1977; 74: 1729–1733
   Google Scholar
• Vermeulen A, Goemaere S, Kaufman J M. Sex hormones, body composition and aging. The Aging Male 1999; 2: 8–16
   Google Scholar
• Van den Beld A W, de Jong F H, Grobbee D E, Pols H A, Lamberts S W. Measures of bio-available testosterone and estradiol and their relationships with muscle strength, bone density and body composition in elderly men. J Clin Endocrinol Metab 2000; 85: 3276–3282
   PubMed Web of Science ®Google Scholar
• Stellato R K, Feldman H A, Hamdy O, Horton E S, McKinlay J B. Testosterone, sex-hormone-binding globulin and the development of type 2 diabetes mellitus in middle-aged men. Diabetes Care 2000; 23: 490–494
   PubMed Web of Science ®Google Scholar
• Laaksonen D E, Niskanen R, Purnonen K, Nuyssönen K, Tuomainen T P, Valkonen V P, Salonen R, Salonen J T. Testosterone and sex-hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004; 27: 1036–1041
   PubMed Web of Science ®Google Scholar
• Gyllenborg J, Rasmussen S L, Borch-Johnsen K, Heitmann B L, Skakkebaek N E, Juul A. Cardiovascular risk factors in men: the role of gonadal steroids and sex hormone-binding globulin. Metabolism 2001; 50: 882–888
   PubMed Web of Science ®Google Scholar
• Simon D, Charles M A, Nahoul K, Orssaud G, Kremski J, Hully V, Joubert E, Papoz L, Eschwege E. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. J Clin Endocrinol Metab 1997; 82: 682–685
   PubMed Web of Science ®Google Scholar
• Tchernof A, Labrie F, Belanger A, Prud'homme D, Bouchard C, Tremblay A, Nadeau A, Despres J P. Relationships between endogenous steroid hormone, sex hormone-binding globulin and lipoprotein levels in men: contribution of visceral obesity, insulin levels and other metabolic variables. Atherosclerosis 1997; 133: 235–244
   PubMed Web of Science ®Google Scholar
• Zmuda J M, Cauley J A, Kriska A, Glynn N W, Gutai J P, Kuller L H. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13 year follow-up of former multiple risk factor intervention trial participants. Am J Epidemiol 1997; 146: 609–617
   PubMed Web of Science ®Google Scholar
• Khaw K T, Barrett-Connor E. Blood pressure and endogenous testosterone in men: an inverse relationship. J Hypertens 1988; 6: 329–332
   PubMed Web of Science ®Google Scholar
• Haffner S M, Garg A, Peshock R M, Grundy S M. Sex steroid hormones, upper body obesity, and insulin resistance. J Clin Endocrinol Metab 2002; 87: 4522–4527
   PubMed Web of Science ®Google Scholar
• Mulligan T, Frick M F, Zuraw Q C, Stemhagen A, Mcwhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006; 60: 762–769
   PubMed Web of Science ®Google Scholar
• Kaplan S A, Meehan A G, Shah A. The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the implications for the relatively high incidence of erectile dysfunction observed in these men?. J Urol 2006; 176(4 Pt 1)1524–1527, discussion 1527–1528
   PubMed Web of Science ®Google Scholar
• Cohen P G. Aromatase, adiposity, aging and disease. The hypogonadal metabolic-atherogenic-disease and aging connection. Med Hypotheses 2001; 56: 702–708
   PubMed Web of Science ®Google Scholar
• Holmang A, Bjorntorp P. The effects of testosterone on insulin sensitivity in male rats. Acta Physiol Scand 1992; 146: 505–510
   PubMedGoogle Scholar
• Muller Grobbee D E, den Tonkelaar I, Lamberts S WJ, van der Schouw Y T. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 2005; 90: 2618–2623
   PubMed Web of Science ®Google Scholar
• Oh J Y, Barrett-Connor E, Wedick N M, Wingard D L. Endogenous sex hormones and the development of type 2 diabetes in older men and women; The Rancho Bernardo study. Diabetes Care 2002; 25: 55–60
   PubMed Web of Science ®Google Scholar
• Kupelian V, Page S T, Araujo A B, Travison T G, Bremner W J, McKinlay J B. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006; 91(3)843–850
   PubMed Web of Science ®Google Scholar
• Haffner S M, Valdez R A, Mykkanen L, Stern M P, Katz M S. Decreased testosterone and dehydroepiandrosterone sulfate concentrations are associated with increased insulin and glucose concentrations in nondiabetic men. Metabolism 1994; 43: 599–603
   PubMed Web of Science ®Google Scholar
• Haffner S M, Mykkanen L, Valdez R A, Katz M S. Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. J Clin Endocrinol Metab 1993; 77(6)1610–1615
   PubMed Web of Science ®Google Scholar
• Muller M, Grobbee D E, den Tonkelaar I, Lamberts S WJ, van der Schouw Y T. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 2005; 90: 2618–2623
   PubMed Web of Science ®Google Scholar
• Smith J C, Bennett S, Evans I M, Kynaston H G, Parmar M, Mason M D, Cockcroft J R, Scanlon M F, Davies J S. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. JCEM 2001; 86: 4261–4267
   PubMed Web of Science ®Google Scholar
• Keating N L, O'Malley A J, Smith M R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24(27)4448–4456
   PubMed Web of Science ®Google Scholar
• Braga-Basaria M, Dobs A S, Muller D C, Carducci M A, John M, Egan J, Basaria S. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006; 24(24)3979–3983
   PubMed Web of Science ®Google Scholar
• Dockery F, Bulpitt C J, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (London) 2003; 104(2)195–201
   PubMed Web of Science ®Google Scholar
• Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto A M, Snyder P J, Weber T, Berman N, Hull L, Swerdloff R S. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004; 89: 2085–2098
   PubMed Web of Science ®Google Scholar
• Bhasin S. Androgen treatment of hypogonadal men. J Clin Endocrinol Metab 1992; 74: 1221–1224
   PubMed Web of Science ®Google Scholar
• Bhasin S J, Buckwalter G. Testosterone supplementation in older men: a rational idea whose time has not yet come. Am J Physiol Endocrinol Metab 2001; 281: E1172–E1181
   PubMed Web of Science ®Google Scholar
• Isidori A M, Giannetta E, Greco E A, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A, Fabbri A. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol 2005; 63: 280–293
   PubMed Web of Science ®Google Scholar
• Wang C, Swerdloff R S, Iranmanesh A, Dobbs A, Snyder P J, Cunningham G, Matsumoto A M, Weber T, Berman N. Transdermal testosterone gel improves sexual function, mood, muscle strength and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000; 85: 2839
   PubMed Web of Science ®Google Scholar
• Snyder P J, Peachy H, Hannoush P, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999; 84: 2647–2653
   PubMed Web of Science ®Google Scholar
• Woodhouse L J, Gupta N, Bhasin M, Singh A B, Ross R, Phillips J, Bhasin S. Dose-dependent effects of testosterone on regional adipose tissue distribution in healthy young men. J Clin Endrocrinol Metab 2004; 89: 718–726
   PubMed Web of Science ®Google Scholar
• Tenover J S. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992; 75: 1092–1098
   PubMed Web of Science ®Google Scholar
• Kapoor D, Goodwin E, Channer K S, Jones T H. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006; 154(6)899–906
   PubMed Web of Science ®Google Scholar
• Marin P, Holmang S, Jonsson L, et al. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord 1992; 16: 991–997
   PubMed Web of Science ®Google Scholar
• Boyanov M A, Boneva Z, Christov V G. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003; 6: 1–7
   PubMedGoogle Scholar
• Mudali S, Dobs A S. Effects of testosterone on body composition of the ageing male. Mech Ageing Dev 2004; 125: 297–304
   PubMed Web of Science ®Google Scholar
• Luukka V, Personen U, Huhtaniemi I. Inverse correlation between serum testosterone and leptin in men. J Clin Endocrinol Metab 1998; 81: 4433
   Google Scholar
• Hislop M S, Rantanjee B D, Soule S G, Marais A D. Effects of anabolic-androgenic steroid use or gonadal testosterone suppression on serum leptin concentration in men. Eur J Endocrinol 1999; 141: 40–46
   PubMed Web of Science ®Google Scholar